E-DRUG: New approaches to filling the gap in TB drug discovery
--------------------------------------------------------------
In this week's magazine section, PLoS Medicine publishes three policy papers arising from a recent Médecins Sans Frontières/Doctors Without Borders (MSF) symposium on the urgent need to develop new drugs for tuberculosis.
The first concerns "New approaches to filling the gap in TB drug discovery", and sees promise in this week’s talks at the WHO Intergovernmental Working Group on a global R&D framework treaty.
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040293
The second article “Randomized trials to Optimize Treatment of MultiDrug-Resistant Tuberculosis” calls for clinical trials of new regimens for treating MDR-TB.
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040292
A third article highlights the need for an urgent and massive expansion of clinical trials capacity to accelerate the development and evaluation of new TB drugs.
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040302
Please find below a press release from PLoS.
------------------
FROM THE PLOS MEDICINE MAGAZINE SECTION
In this week's magazine section, PLoS Medicine publishes three policy papers arising from a recent Médecins Sans Frontières/Doctors Without Borders (MSF) symposium on the urgent need to develop new drugs for
tuberculosis:
A new approach to overcoming the bottlenecks in the search for TB drugs
Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs for tuberculosis, say Martina Casenghi (MSF) and colleagues.
The lack of candidate compounds is "cause for alarm," they say, given the global emergence of strains of TB that are resistant to current TB drugs.
The authors argue that the few drug companies engaged in TB drug development are risk averse, generally embarking on drug development only when given evidence of rigorously validated targets and lead compounds that inhibit them. As a result, it has fallen largely to academia to undertake early stage drug discovery.
Alternative approaches are needed, say Casenghi and colleagues, to stimulate research and development of TB drugs. They lay out one such approach, which they call "open-access drug discovery entities," in which academia and industry collaborate and share their results at the earliest opportunity. "One way to ensure that priority medical needs are met while providing economic incentives," say the authors, "is to register resulting patents under a patent track that rewards products based on the impact they have in reducing the global burden of disease."
Massive expansion of clinical trials capacity is urgently needed
An urgent and massive expansion of clinical trials capacity is needed to carry out vital research to accelerate the development and evaluation of new TB drugs, say Unni Karunakara (MSF) and colleagues.
"Trials are urgently needed,” they say, “to find regimens that are shorter, less toxic, and effective against multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB)." Trials are also needed, they argue, to find new TB treatment regimens for children, for those with TB and HIV co-infection, and those with TB occurring outside the lungs (extra-pulmonary TB).
Unfortunately, say the authors, only about US $20-30 million was spent in 2005 around the world for TB clinical trials. The authors call for funding of at least US $300-500 million annually for a TB trials agenda. Direct investment is also needed, they say, in the infrastructure required to conduct trials.
The time is right for trials of multidrug-resistant TB therapy
Drug-resistant TB strains may account for 10% of the 8 million new cases of TB that occur each year, say Carole Mitnick (Harvard Medical School, Boston, USA) and colleagues. Increasing concern about resistance has redoubled interest in strategies to control drug-resistant TB, they say, especially in settings of high HIV prevalence.
Current treatments for MDR-TB last between 18 and 24 months, adverse effects are common, and many patients cannot be cured.
However, the time is now right, say Mitnick and colleagues, to conduct randomized clinical trials of new regimens for treating MDR-TB. For a start, MDR-TB treatment programs have expanded dramatically: 40 programs in resource-limited settings are managing treatment for nearly 30,000 patients. These treatment programs provide the settings in which trails can be implemented. In addition, for the first time in 30 years, several new drug classes hold promise for MDR-TB treatment.
"Four elements are needed," say the authors, "to make MDR-TB treatment trials a reality: money; additional work on the drug pipeline; rigorous, interdisciplinary preclinical work on individual agents and regimens; and an understanding that TB clinical trials need not be a zero–sum endeavor."